Literature DB >> 16870545

Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.

J M Cervera Grau1, G Galiana Esquerdo, C Llorca Ferrándiz, H Briceño García, M Díaz Castellano, P Férriz Moreno.   

Abstract

A 75-year-old woman was diagnosed of MCD plasma cell (PC) variant with B symptoms. Diffuse lymph-node enlargement, splenomegaly and pancytopenia were detected. Induction with Rituximab was made because pancytopenia was present. Actually patient is free of disease. This is the first complete response of MCD published, VIH negative, induced with anti CD20.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16870545     DOI： 10.1007/s12094-006-0056-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  6 in total

1.  Multicentric Castleman's disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patient.

Authors:  D P Kofteridis; N Tzagarakis; I Mixaki; E Maganas; E Xilouri; E N Stathopoulos; G D Eliopoulos; A Gikas
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

2.  Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.

Authors:  M Corbellino; G Bestetti; C Scalamogna; S Calattini; M Galazzi; L Meroni; D Manganaro; M Fasan; M Moroni; M Galli; C Parravicini
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

3.  Tropism of human herpesvirus 8 for peripheral blood lymphocytes in patients with Castleman's disease.

Authors:  H Kikuta; O Itakura; K Taneichi; M Kohno
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

4.  Rituximab therapy for HIV-associated Castleman disease.

Authors:  Anne-Geneviève Marcelin; Laurent Aaron; Christine Mateus; Emmanuel Gyan; Isabelle Gorin; Jean-Paul Viard; Vincent Calvez; Nicolas Dupin
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

5.  A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.

Authors:  Dany Gholam; Jean-Marie Vantelon; Ahmad Al-Jijakli; Jean-Henri Bourhis
Journal:  Ann Hematol       Date:  2003-07-30       Impact factor: 3.673

6.  Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.

Authors:  R Seggewiss; A D Ho; A Kraemer
Journal:  Ann Hematol       Date:  2003-11-13       Impact factor: 3.673
  6 in total
  3 in total

1.  HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.

Authors:  Paolo Nicoli; Ubaldo Familiari; Marco Bosa; Tiziano Allice; Francesca Mete; Alessandro Morotti; Daniela Cilloni; Giuseppe Saglio; Angelo Guerrasio
Journal:  Int J Hematol       Date:  2009-09-12       Impact factor: 2.490

2.  Sjögren's and plasma cell variant Castleman disease: a case report.

Authors:  Yvonne A Dei-Adomakoh; Leslie Quarcoopome; Afua D Abrahams; Catherine I Segbefia; Dzifa I Dey
Journal:  Ghana Med J       Date:  2018-03

3.  Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.

Authors:  Ruchi Sood; Harris C Taylor; Hamed Daw
Journal:  Case Rep Hematol       Date:  2013-10-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.